This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Evaluate Tolerability of Myfortic®/Simulect® and Tacrolimus Without Steroids in Three Patient Populations

This study has been terminated.
(Study terminated due to slow enrollment)
Novartis Pharmaceuticals
Information provided by (Responsible Party):
The University of Texas Medical Branch, Galveston Identifier:
First received: June 8, 2011
Last updated: September 30, 2013
Last verified: September 2013
This study is designed to evaluate the tolerability of Myfortic®/Simulect® combination in diabetic patients in a steroid free regimen. Due to the diverse ethnicity of our transplant recipient population, our study will determine any different responses, including autoimmunity, between Hispanic, and Caucasian, patients.

Condition Intervention Phase
Diabetes Immunosuppression Procedure: Gastric emptying test Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Study to Evaluate Tolerability of Myfortic With Simulect Induction and Tacrolimus Without Steroids in Three Patient Populations; 1: Kidney/Pancreas Transplants,2: Diabetic Kidney Transplants, and 3: Non-diabetic Kidney Transplants

Further study details as provided by The University of Texas Medical Branch, Galveston:

Primary Outcome Measures:
  • Tolerability of Myfortic in combination with Simulect and Tacrolimus without steroids [ Time Frame: 24 months ]
    Assure that immunosuppression protects graft function by decreased incidence of rejection and side effects

Secondary Outcome Measures:
  • GI complications [ Time Frame: 24 months ]
    Gastric emptying test

  • Graft function [ Time Frame: 24 months ]

    Renal function assessed by serum creatinine and calculating creatinine clearance.

    Pancreas function assessed by glucose control, exogenous insulin requirement, HgbA1C

  • Biopsy proven rejection [ Time Frame: 24 months ]
    Renal graft core biopsy will be performed on all suspected rejection.

Enrollment: 2
Study Start Date: March 2011
Study Completion Date: October 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Transplant recipients
All subjects receive identical drug treatment
Procedure: Gastric emptying test
Gastric emptying tests will be performed at baseline, 6 months and 12 months
Other Name: Gastric motility

Detailed Description:
Myfortic® is an enteric-coated formulation of the sodium salt derivative of mycophenolic acid (MPA) that is administered to control kidney graft rejection. Myfortic® was developed to improve MPA-related upper gastrointestinal (GI) side effects by delaying the release of MPA until it reaches the large surface of the small bowel. Approximately half of all the kidney transplant recipients in the United States have diabetes mellitus. A recent analysis of approximately 30,000 kidney transplant recipients included in the U.S. Renal Data System showed that 42% of patients had pre-transplant diabetes (1). Moreover, 15% to 20% of patients develop diabetes after transplantation, a condition that is commonly known as post-diabetes mellitus (1-3). It was previously shown that the rate and extent of MPA absorption is minimally affected by diabetes (4). Limited data is available in the current literature on Myfortic® and Simulect® based therapy in diabetic patients.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Adults (age 18 to 65 years of age), male or female Hispanic or Caucasian.
  2. Primary kidney or kidney transplant patients (cadaveric, living related, or living unrelated)
  3. Written inform consent obtained. The patients are willing to participate in the study at UTMB.
  4. Female with negative pregnancy test.
  5. PRA < 20 %.
  6. En-blocks and two kidneys (tx'd at the same time) will be allowed.
  7. Cold Ischemia time ≤ 30 hrs
  8. Hep C patients will be allowed to enroll in this study

Exclusion Criteria:

  1. Multi-organ transplants
  2. Transplant from non-heart beating donor (NHBD) or dual transplants
  3. A-B-O incompatible or positive cross match
  4. Conditions which significantly alter the absorption, distribution, and metabolism (except for diarrhea) of medications.
  5. Women of childbearing potential not using contraception method(s) as well as women who are breastfeeding
  6. Inability to tolerate oral medications
  7. Inability to sign a written consent form or to cooperate with investigators
  8. Use of an investigational medication in the past 30 days.
  9. Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study (specify as required)
  10. HIV positive patients
  11. History of psychosocial instability
  12. Mental incompetence
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01387659

United States, Texas
University of Texas Medical Branch
Galveston, Texas, United States, 77555
Sponsors and Collaborators
The University of Texas Medical Branch, Galveston
Novartis Pharmaceuticals
Principal Investigator: Luca Cicalese, MD University of Texas
  More Information

Responsible Party: The University of Texas Medical Branch, Galveston Identifier: NCT01387659     History of Changes
Other Study ID Numbers: 10-244
Study First Received: June 8, 2011
Last Updated: September 30, 2013

Keywords provided by The University of Texas Medical Branch, Galveston:
Gastric emptying
Gastric motility

Additional relevant MeSH terms:
Mycophenolate mofetil
Mycophenolic Acid
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Calcineurin Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antibiotics, Antineoplastic
Antineoplastic Agents processed this record on September 21, 2017